-
News list
-
Global Investor Forum Life Science in Maastricht
-
ILYA Pharma won the ATTD Startup grant
-
ILYA Pharma receives a grant from VINNOVA
-
PharmabioticsGlobal 2017
-
ILYA Pharma presents at NGM Live tomorrow May 16
-
Professor Mia Phillipson in the studio at the presentation of the Nobel Prize Laureates in Physiology or Medicine
-
ILYA Pharma wins SweLife Accelerator grant
-
Ilya Pharma is awarded three million euros from H2020 EU SME programme
-
The innovation and the MOA published by high ranking scientific journal PNAS
-
The CEO of Ilya Pharma ranked #20 top entrepreneur in Sweden
-
Ilya Pharma in the hot spot
-
Female entrepreneurs leading the way
-
SwedenBIO Award 2018
-
New project manager
-
Celebration of safety- and efficacy data from the last preclinical study
-
ILYA Pharma will present at the Nordic Life Science Days
-
ILYA Pharma is growing and recruiting
-
A platform for new biologics and technology innovations
-
Ilya Pharma raises additional Euro 3 million to take novel ATMP through to Phase II for wound care
-
Ilya Pharma is presenting at "INNOVATIONS IN WOUND HEALING 2018" FL 7-10 dec.
-
Ilya Pharma is opening a new indication and recruits a post doctoral scientist with focus on IBD
-
Selected top 500 globally of emerging companies in deep tech, Hello Tomorrow challenge
-
Evonik 2019
-
EIC Investor Day@Nasdaq
-
Advanced Wound Care Seminar Redeye in Stockholm
-
Hello Tomorrow Investor day
-
Ilya Pharma winner at Hello Tomorrow Global Challenge 2019
-
Ilya Pharma will present at the 29th Conference of the European Wound Management Association, Gothenburg 5-7 June
-
Ilya Pharma will present at Nordic Life Science Days 11-12 September, Malmö
-
Ilya Pharma selected to present at Biopharm America/Boston Biotech week 9-12 September
-
Ilya Pharma - one of the selected 30 most innovative companies, RESI2019, Boston Biotech Week
-
Ilya Pharma will present clinical developments at Bio Investor Forum SF 22-23 October
-
Ilya Pharma selected top Innovator and will present at the New England Venture Summit December 4 in Boston
-
Ilya Pharma will present new data and development plans for our ILP100 candidate at IBD Innovate, organised by Chrones and Colitis Foundation, NYC 4th of December
-
Evelina Vågesjö and the achievements of Ilya Pharma recognised by MIT Tech Review Innovators under 35
-
Ilya Pharma selected to present at the IMCAS Congress Innovation Shark Tank in Paris, 31st Jan 2020
-
Ilya Pharma will present recent clinical data at Advanced Therapies Congress & Expo 2020 in London March 31
-
Ilya Pharma will present developments at SwissNordicBio 6th of February 2020 in Zuric
-
Ilya Pharma selected to present at the BIO CEO Investor forum in NYC 10-11th of February.
-
Ilya Pharma’s ILP100 Phase I wound care therapy trial progresses swiftly to multiple dosing
-
COVID-19
-
Operational Report Q1 2020
-
Resuming recruitment to the ongoing clinical trial - final cohorts
-
Ilya Pharma awarded Euros 5.3 million from EIC Accelerator to fast track Phase II study of first-in-class ILPI100 advanced therapy for wound treatment in people with diabetes
-
Ilya Pharma awarded risk-shared funding by EIT Health
-
Operational Report Q2 2020
-
Meet Margareth Jorvid - leading innovations to products
-
Some thoughts from the CEO
-
Meet Ingemar Kihlstörm - facilitating the next stage of growth
-
Operational Report Q3 2020
-
FDA open to new endpoints for patients with difficult wounds
-
Latest clinical developments and next raise to be presented at EIC Investor Day 2.0 17-18 December
-
Ilya Pharma will present at the Swiss Nordic Bio 10-11 February 2021
-
Meet Stefan Roos co-founder and innovator for multiple patents of commercial strains of lactic acid bacteria
-
Ilya Pharma extends research collaboration with Uppsala University
-
Ilya Pharma presented at the Redeye unlisted event December 2
-
Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II
-
Ilya Pharma approved for funding by the European Innovation Council Equity Fund for high-impact innovation
-
Ilya Pharma awarded European patent covering engineered Lactobacillus reuteri strains for use in cutaneous wound therapy
-
Ilya Pharma will present at Bio€quity Europe Digital 17-19 May
-
Ilya Pharma will present at Nordic Life Science Invest Digital 19 April 2021
-
Ilya Pharma will present recent clinical data and planned studies for ILP100 Topical and Oral at Pharmabiotics 28-29 April 2021
-
Pfizer veteran Sylvia McBrinn joins Board while Oskar Lund becomes CFO as Ilya Pharma strengthens senior management - top news shared by FirstWord Pharma
-
Ilya Pharma Receives Approval from Swedish Regulators to Initiate Phase II Clinical Study of ILP100 Gene Therapy to Treat Difficult Wounds Patients with Diabetes
-
Open position - Senior Clinical Trials Manager for phase II/III study
-
Ilya Pharma will present at Microbiome Movement 3-5 August
-
Ilya Pharma selected to present at BioFuture 4-8 October in NYC at Cure in the session of "Breakthrough Therapies: Brought to you by Game Changing Technologies!
-
Ilya Pharma will be participating at the Swedish American Life Science Summit 2021 October 20-22 and is nominated to the Rising Star Award
-
Ilya Pharma will be participating at Jefferies London Healthcare Conference 16-19 November
-
Professor Mia Phillipson will present Nature Conferences Innovative Tissue Therapies from Bench to Bedside 16-18 November
-
Ilya Pharma shares latest developments of ILP100-Oral at virtual conference 7th of December showcasing innovations in gut therapeutics
-
Ilya Pharma will present clinical and corporate updates at Biotech Showcase 10-13 January at JPM Week 2022
-
Ilya Pharma invited to attend the 40th JP Morgan Health Care Conference 10-13 January, 2022
-
Open position as CMC project manager
-
Ilya Pharma presenting at Hybrid event BIO CEO Investor conference in NYC 14-17 February 2022
-
Ilya Pharma participating in Texas Life Science Forum, Houston 23-24 February 2022
-
Scientific abstract of ILP100-Oral in two colitis models selected for poster at Experimental Biology Philadelphia April 4 2022
-
8.5 MEUR to advance our three programs
-
Ilya Pharma makes strategic investment in bioanalytical company
-
FDA clearance of IND for first-in-class ILP100-Topical immunotherapy treatment of surgical wounds in patients with prediabetes, diabetes and obesity
-
Ilya Pharma present at BIO San Diego 13-16 June
-
Labiotech.eu reports on Ilya Pharmas latest new patents covering major markets
-
Ilya Pharma presents poster at US Military Health System Research Symposium in Florida September 12
-
Ilya Pharma appoints Leo Groenewegen as CEO of recent acquisition Nordic Bioanalysis
-
Ilya Pharma at Nordic Life Science Days Malmö 28-29 September
-
Ilya Pharma will present company updates at BioFuture hosted live in NYC 7-8 November and virtually 14-16 November
-
Ilya Pharma will attend Jefferies Health Care Conference in London 15-16 Nov
-
Ilya Pharma is present at the 2023 JPM week in San Francisco 9-13 January
-
Ilya Pharma have been granted a preIND meeting with the FDA related to the development of ILP100-Oral
-
Ilya Pharma will participate at AMWC 2023 - 21st Aesthetic & Anti-Aging Medicine World Congress
-
Abstract selected for poster presentation at International Society for Cell- and Gene Therapy 2023 London May 2023
-
Media
-
About cookies
-
Personer
